Fig. 4: α_V^high tumours promote TIL exclusion and decreased T cell proliferation and activation.

a Left, B16F10E and B16F10E-KO tumour growth kinetics (p = 0.800). Right, tumour weights of B16F10E and B16F10E-KO tumours recovered at day 14 after engraftment (p = 0.846). Tumour volumes and tumour weights are given as means ± SEM of eight mice/group. Data represent one independent experiment out of three. b The ratio of active versus total TGF-β from B16F10E and B16F10E-KO tumours (n = 8) was measured ex vivo on day 8 by ELISA (*p = 0.038). c Absolute cell counts of CD3⁺ (*p = 0.040) and CD8⁺ T cells (*p = 0.034) infiltrating B16F10E and B16F10E-KO tumours (n = 8). Data are from one independent experiment out of three. d Representative flow cytometry profiles (bi-exponential scale) of the expression of CD62L and CD44 in CD8⁺ T cells from B16F10E and B16F10E-KO tumours (n = 8). Right, percentage of CD44⁺CD62L^neg cells among CD8⁺ T cells in B16F10E and B16F10E-KO (***p = 0.0006). e KLRG1 (n = 18, *p = 0.014), CD69 (n = 13, *p = 0.025) and CD103 (n = 17, ***p = 0.0003) expression in CD8⁺ T cells infiltrating B16F10E and B16F10E-KO tumours. Data are from two independent experiments out of three. f Representative flow cytometry profiles of PD-1 expression on CD8⁺ TIL from B16F10E and B16F10E-KO. Right, expression of PD-1 on CD8⁺ T cells infiltrating B16F10E and B16F10E-KO tumours (n = 12, *p = 0.016). g Representative profiles of Ki-67 expression in CD8⁺ T cells from B16F10E and B16F10E-KO. Right, expression of Ki-67 in CD8⁺ T cells from B16F10E and B16F10E-KO tumours (n = 11, *p = 0.028). Data are from two independent experiments out of three. Each symbol represents an individual tumour (a−g.). Horizontal lines correspond to mean ± SEM (a, right−g.). Data were calculated with unpaired Student t-tests (a, right−g.) and two-way ANOVA (a, left). Source data are provided as a Source Data file.